Research Article| Volume 44, ISSUE 3, P149-154, November 1991

Effects of diltiazem on thromboxane B2 production from platelet-rich plasma and whole blood

      This paper is only available as a PDF. To read, Please Download here.


      The present study evaluated the effects of the calcium-channel blocking agent diltiazem on platelet aggregation and on synthesis of thromboxane B2 (the stable metabolite of thromboxane A2) from platelet-rich plasma (PRP) and whole blood samples. Our results showed that diltiazem inhibits collagen- and thrombin-induced platelet aggregation and TXB2 production from PRP. Since no significant interference with conversion of arachidonate to thromboxane A2 was demonstrated, inhibition of phospholipase A2 activity may be the prevailing mechanism of the diltiazem effect. The drug demonstrated a dose-related inhibitory activity on TXB2 synthesis from whole blood samples during spontaneous clotting or following stimulation with collagen or thrombin. The present results give further evidences for an antiplatelet activity of diltiazem and support the hypothesis that inhibition of platelet function contributes to the therapeutic efficacy of this drug in the treatment of cardiovascular diseases.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hamberg M
        • Svensson J
        • Samuelsson B
        Thromboxanes a new group of biologically active compounds derived from prostaglandin endoperoxides.
        in: 2nd ed. Proceedings of the National Academy of Sciences USA. 72. 1975: 2294-2298
        • Svensson J
        • Hamberg M
        • Samuelsson B
        On the formation and effects of thromboxane A2 in human platelets.
        Acta Physiologica Scandinavica. 1976; 98: 285-294
        • Hirsch PD
        • Hillis LD
        • Campbell WB
        • Firth BG
        • Willerson JT
        Release of prostaglandins and thromboxane into the coronary circulation in patients with ischaemic heart disease.
        New England Journal of Medicine. 1981; 304: 685-691
        • Vesterqvist O
        • Green K
        Urinary excretion of 2–3-dinor-thromboxane B2 in and under normal conditions, following drugs and during some pathological conditions.
        Prostaglandins. 1984; 27: 627-635
        • Fitzgerald DJ
        • Ro L
        • Catella F
        • FitzGerald GA
        Platelet in unstable coronary disease.
        New England Journal of Medicine. 1986; 315: 983-989
        • Reilly IAG
        • Roy L
        • FitzGerald GA
        Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.
        British Medical Journal. 1986; 292: 1037-1039
        • Pepine CJ
        • Feldman RL
        • Whittle J
        • Curry RC
        • Conti RC
        Effect of calcium antagonist diltiazem in patients with variant angina.
        American Heart Journal. 1981; 101: 719-724
        • Kiyomoto A
        • Sasaki Y
        • Odawara A
        • Morita T
        Inhibition of platelet aggregation by diltiazem: comparison with verapamil and nifedipina and inhibitory potencies of diltiazem metabolites.
        Circulation Research. 1983; 5: 115-119
        • Mehta J
        • Mehta P
        • Ostrowski N
        Calcium blocker diltiazem inhibits platelet activation and stimulates vascular prostacyclin synthesis.
        American Journal Medical Sciences. 1986; 291: 20-24
        • Anfossi G
        • Trovati M
        • Mularoni E
        • Massucco P
        • Cavalot F
        • Mattiello
        • Emanuelli G
        Studies on inhibition of human platelet response by diltiazem.
        General Pharmacology. 1990; 21: 949-954
        • Ring ME
        • Corrigan JJ
        • Fenster PE
        Effects of oral diltiazem on platelet function: alone and in combination with low dose aspirin.
        Thrombosis Research. 1986; 44: 391-400
        • Packham MA
        • Mustard FJ
        Pharmacology of platelet-affecting drugs.
        Circulation. 1980; 62: V26-V41
        • Adams GA
        Platelet aggregation.
        in: Longenecker GL The platelets. Physiology and Pharmacology. Academic Press, Orlando1985: 1
        • Higgs GA
        • Bunting S
        • Moncada S
        • Vane JR
        Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis.
        Prostaglandins. 1976; 11: 749-757
        • Goldstein JM
        • Mahnsten CL
        • Kindahl H
        • Kaplan HB
        • Radmark O
        • Samuelsson B
        • Weissmann G
        Thromboxane generation by human peripheral blood polymorphonuclear leukocytes.
        Journal of Experimental Medicine. 1978; 148: 787-792
        • Vicenzi E
        • Biondi A
        • Bordignon C
        Human mononuclear phagocytes from different anatomical sites differ in their capacity to metabolize arachidonic acid.
        Clinical and Experimental Immunology. 1984; 57: 385-392
        • Pattison A
        • Eason CT
        • Bonner W
        The in vitro effect of amrinone on thromboxane B2 synthesis in human whole blood.
        Thrombosis Research. 1986; 42: 817-821
        • Born GVR
        Aggregation of whole blood platelets by adenosine diphosphate and its reversal.
        Nature. 1962; 194: 927-929
        • Thompson SG
        • Vickers MV
        Methods in dose response platelet aggregometry.
        Thrombosis and Haemostasis. 1985; 54: 216-218
        • Meade G
        • Stirling Y
        • Haines AP
        • Miller GJ
        Epidemiological characteristics of platelet aggregability.
        British Medical Journal. 1985; 290: 428-432
        • Kohno K
        • Takenchi J
        • Etoh A
        • Noda K
        Pharmacokinetics and bioavailability of diltiazem (CRD-401) in dog.
        Arzneimittel-Forschung/Drug Research. 1977; 27: 1424-1428
        • Rittenhouse S
        • Deykin D
        The activation by Ca2+ of platelet phospholipase A2. Effects of dibutyryl cyclic adenosine monophosphate and 8-(N,N-diethylamino)-octyl-3,4,5-trimethoxybenzoate.
        Biochimica et Biophysica Acta. 1978; 543: 409-422
        • Dahl ML
        • Votila P
        Thromboxane formation during blood clotting is decreased by verapamil.
        Prostaglandins, Leukotrienes and Medicine. 1984; 13: 217-218
        • Anfossi G
        • Trovati M
        • Mularoni E
        • Massucco P
        • Calcamuggi G
        • Emanuelli G
        Influence of propranolol on platelet aggregation and thromboxane B2 production from platelet-rich plasma and whole blood.
        Prostaglandins, Leukotrienes and Essential Fatty Acids. 1989; 36: 1-7
        • Saniabadi AR
        • Belch JJR
        • Lowe GDO
        • Barbenel JC
        • Forbes CD
        Comparison of inhibitory action of prostacyclin and a new prostacyclin analogue on the aggregation of human platelets in whole blood.
        Haemostasis. 1987; 17: 147-151
        • Walley TJ
        • Woods KL
        • Barnett DB
        Effects of calcium channel blockers on in vitro platelet function in whole blood using single platelet counting.
        Thrombosis and Haemostasis. 1989; 61: 137-139
        • Hawiger J
        Formation and regulation of platelet and haemostatic plug.
        Human Pathology. 1987; 18: 111-120
        • Zucker MB
        • Borrelli J
        Platelet clumping produced by connective tissue suspension and by collagen.
        in: 2nd ed. Proceedings of the Society for Experimental Biology and Medicine. 109. 1963: 779-781
        • Vargaftig BB
        • Lefort J
        • Joseph D
        • Fouque D
        Mechanisms of bronchoconstriction and of thrombocytopenia induced by collagen in the guinea pig.
        European Journal of Pharmacology. 1978; 58: 273-284
        • Mevers KM
        • Seachord CL
        • Holmsen H
        • Smith JB
        • Preur DJ
        A dominant role of thromboxane formation in secondary aggregation of platelets.
        Nature. 1979; 282: 331-333
        • Svensson J
        • Hamberg M
        Thromboxane A2 and prostaglandin H2: potent stimulators of the swine coronary artery.
        Prostaglandins. 1976; 12: 943-950
        • Mehta J
        • Mehta P
        • Feldman RL
        • Horalek C
        Thromboxane release in coronary artery disease: spontaneous versus pacing-induced angina.
        American Heart Journal. 1984; 107: 286-292
        • Robertson RM
        • Robertson
        • Roberts LJ
        • Maas RL
        • FitzGerald GA
        • Friesenger GG
        • Oates JA
        Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials.
        New England Journal of Medicine. 1981; 304: 998-1003
        • Davies MJ
        • Thomas A
        Thrombosis and acute coronary-artery lesions in sudden cardiac ischaemic death.
        New England Journal of Medicine. 1984; 310: 1137-1140
        • Coker SJ
        • Parrat JR
        • Ledingham IM
        • Zeitling IJ
        Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium.
        Journal of Molecular and Cellular Cardiology. 1982; 14: 483-488